Live In Play

Live In Play®

Updated: 23-Jun-21 08:38 ET

LMNL: Liminal BioSciences announces signature of a share purchase agreement for sale of remaining plasma-derived business with Kedrion (4.09)

Co announced Kedrion has exercised its option to acquire the remainder of the Company's plasma-derived business under the terms of the Share Purchase Agreement entered into by the Company and Kedrion.
This acquisition would include the Ryplazim business operated through its subsidiaries, Prometic Bioproduction Inc., the Company's plasma-derived therapeutics manufacturing facility, and Prometic Biotherapeutics.
On June 4, 2021, Ryplazim was approved by the U.S. Food and Drug Administration (FDA) as the first treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia).